ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates.

Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT
  
Pre-Registration: Participants can pre-register for the conference call :
  
 Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
  
Dial In:Those who choose not to pre-register can access the live conference call by dialing the following and requesting the SeaStar Medical call:
 866-777-2509 within the U.S.
 412-317-5413 from outside the U.S.
  

The live webcast of the conference call also will be available . A replay of the call will be available for 48 hours beginning two hours after its completion by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 3855739. The webcast will also be archived .

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

Alliance Advisors IR

Jody Cain

(310) 691-7100

# # #



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical Announces Publication in Pediatric Nephrology of Posit...

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI) Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the  in the prestigious, p...

 PRESS RELEASE

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging ...

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of ...

 PRESS RELEASE

SeaStar Medical Announces 2026 Milestones

SeaStar Medical Announces 2026 Milestones Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Desi...

 PRESS RELEASE

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor ...

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time. The live presentation wi...

 PRESS RELEASE

SeaStar Medical Announces 1-for-10 Reverse Split

SeaStar Medical Announces 1-for-10 Reverse Split DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company’s 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company’s common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the mar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch